Open AccessDevelopment of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop
Author(s) -
Chana Weinstock,
Daniel L. Suzman,
Paul G. Kluetz,
John H. Baxley,
Charles J. Viviano,
Amna Ibrahim,
Jonathan P. Jarow,
Raejshwari Sridhara,
Ke Liu,
Peter R. Carroll,
Scott E. Eggener,
Jim C. Hu,
Maha Hussain,
Martin T. King,
Eric A. Klein,
Terry Kungel,
Danil V. Makarov,
Peter A. Pinto,
Brian I. Rini,
Mack Roach,
Howard M. Sandler,
Peter N. Schlegel,
Daniel Y. Song,
Kirsten B. Goldberg,
Richard Pazdur,
Julia A. Beaver
Publication year - 2020
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000000532
Subject(s) - food and drug administration , administration (probate law) , medicine , center of excellence , excellence , drug administration , library science , gerontology , law , political science , pharmacology , computer science
The following is a summary of discussion at a United States FDA (Food and Drug Administration) public workshop reviewing potential trial designs and end points to develop therapies to treat localized prostate cancer.